GENE ONLINE|News &
Opinion
Blog

2022-05-11| Asia-PacificM&A

Bora Pharmaceuticals Expands with Eden Biologics’ CDMO Purchase

by Fujie Tham
Share To

Taiwanese Bora Pharmaceuticals recently announced the establishment of Bora Biologics CDMO platform, and ready to invest $100M to acquire Eden Biologics’ CDMO assets, securing its leading position in Taiwan’s contract development and manufacturing organization (CDMO) market. 

Acquisition of Eden’s CDMO facilities at Hsinchu Biomedical Science Park in Taiwan will jumpstart Bora Group’s first presence in the macromolecules, cell and gene therapy markets, a dramatic and significant shift from the company’s previous focus on small molecule drug manufacturing. With this buy, Bora will obtain cell lines development technologies for protein drugs manufacturing, upstream and downstream processes, quality control setups, etc., components crucial in widening its service offering.

Related article: Cancer Cells Build Nano-Highways to Hijack Mitochondria from Immune Cells

 

Bora’s 5-Year CDMO Growth Project

 

The company has been diversifying rapidly over the past few years, with manufacturing sites set up on multiple continents. Just last month, Bora extended its Oral Solid Dose capabilities to a purpose-built site in Ontario, Canada, with funding for more than $10M over the next 2 years.

Seeking to reduce production costs, drug designers often arrange their manufacturing with CDMOs, for a reduction in costs connected to manufacturing, packaging, and testing, to improve gross margin while maintaining high product and manufacturing quality. In December 2021, the CDMO also acquired a GSK plant in Canada, symbolizing its first manufacturing footprint in Northern America.

Bora’s large share in the manufacturing field certainly will attract drug makers and therapeutics startups to do business with it while bolstering Taiwan’s position in the global pharmaceutical supply chain.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
M&A
Catalent Scoops Up Fellow CDMO, Metrics, for $475 Million
2022-08-11
Roche Dives Deeper into Off-The-Shelf Cell Therapies in Poseida Partnership
2022-08-04
How Governments Around the World Should Respond to the Mounting Costs of Gene and Cell Therapy?
2022-07-08
LATEST
Vaccine Protecting Against 20 Different Pneumococcal Infections Proves Effective in Trial
2022-08-12
FDA Approves Roche’s Established Antiviral For Children Aged Five Or Older
2022-08-12
Novartis Reported Two Deaths Following Zolgensma Gene Therapy
2022-08-12
Extreme Climate Change Is Aggravating Infectious Diseases!
2022-08-11
In Response to Expanding Monkeypox Outbreak, FDA Approves Emergency Use of JYNNEOS Vaccine
2022-08-11
Potential $1 billion Acquisition of TeneoTwo by AstraZeneca comes to Fruition
2022-08-11
Gene Repair Therapy: First Patient Dosed With New Treatment for Sickle Cell Disease
2022-08-11
EVENT
2022-09-09
ESMO 2022 Exhibition
Online and on-side
2022-09-20
Cell & Gene Therapy USA 2022
Virtual
2022-09-21
CSCO Educational Book 2022
Xiamen
2022-09-21
RESI Boston
Boston
2022-09-26
Human Gene Therapy Conference
Australia
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!